Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Rain Therapeutics Q2 EPS $(0.39) Beats $(0.60) Estimate

Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.60) by 35 percent.

byBill Haddad

August 10, 2021

1 minute read

Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.60) by 35 percent.

House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month

By Vandana Singh

April 1, 7:20 AM

The House of Representatives voted to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare.

ANTM

Morgan Stanley Maintains Equal-Weight on CMS Energy, Lowers Price Target to $63

By Benzinga Newsdesk

August 19, 8:30 AM

Morgan Stanley analyst Stephen Byrd maintains CMS Energy (NYSE:CMS) with a Equal-Weight and lowers the price target from $66 to $63.

CMS

News

Intel CEO Says Inventory Burn Drove Server CPU Shipments Down Mid-Single Digit In 2022

By Michael Horton

January 26, 6:13 PM

-Reuters

INTC

News

Greenwich LifeSciences Provides Updates On Recent And Upcoming Developments

By Benzinga Newsdesk

September 9, 6:06 AM

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who

GLSI

Rain Therapeutics Q2 EPS $(0.39) Beats $(0.60) Estimate

Related Posts

House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month

Morgan Stanley Maintains Equal-Weight on CMS Energy, Lowers Price Target to $63

Intel CEO Says Inventory Burn Drove Server CPU Shipments Down Mid-Single Digit In 2022

Greenwich LifeSciences Provides Updates On Recent And Upcoming Developments